Sarepta Therapeutics Reports Q3 2024 Financial Results, Elevidys Revenue Rises to $181M, $210 PT

Sarepta Therapeutics announced its third-quarter 2024 financial results, reporting Elevidys net product revenue of $181 million, up from $122 million in the second quarter. The company highlighted recent corporate developments, including a potential European Union approval for Elevidys in DMD patients aged 3-7 in 2025. Additionally, Sarepta plans to host an R&D Day in 2025 to discuss early-stage assets and anticipates several key catalysts, such as the pivotal Phase 3 EMERGENE Data for SRP-9003 in LGMD2E in the first half of 2025 and a BLA filing for SRP-9003 by mid-2025, with potential approval and launch in 2026. BofA reiterated a Buy rating for Sarepta with a price target of $210, citing strong momentum in the Elevidys launch and projecting a 2026 EPS of 18 bucks.